Rits Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-07-2024
- Paid Up Capital ₹ 5.00 M
as on 16-07-2024
- Company Age 4 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.52 Cr
as on 16-07-2024
- Revenue 674.52%
(FY 2022)
- Profit 4615.79%
(FY 2022)
- Ebitda 2905.09%
(FY 2022)
- Net Worth 38.81%
(FY 2022)
- Total Assets 183.29%
(FY 2022)
About Rits Lifesciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹2.52 Cr.
Ritul Mendapara, Kalpesh Sheta, and Naimish Mendapara serve as directors at the Company.
- CIN/LLPIN
U36999GJ2020PTC114021
- Company No.
114021
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Jun 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Surat, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Rits Lifesciences Private Limited offer?
Rits Lifesciences Private Limited offers a wide range of products and services, including Flavours & Aromatics, Bakery & Confectionery Flavors, Nutraceuticals & Dietary Supplements, Protein Powder, Fitness Supplements, Ayurvedic,Herbal Products & Medicine, Ayurvedic,Herbal Drops & Concentrates, Multivitamin Syrup & Drops, Weight Loss Supplement, Nutritional Supplements.
Who are the key members and board of directors at Rits Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ritul Mendapara  | Director | 18-Jun-2020 | Current |
| Kalpesh Sheta | Director | 01-Mar-2022 | Current |
| Naimish Mendapara | Director | 18-Jun-2020 | Current |
Financial Performance of Rits Lifesciences.
Rits Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 674.52% increase. The company also saw a substantial improvement in profitability, with a 4615.79% increase in profit. The company's net worth Soared by an impressive increase of 38.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rits Lifesciences?
In 2022, Rits Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Jul 2022 | ₹2.52 Cr | Open |
How Many Employees Work at Rits Lifesciences?
Rits Lifesciences has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rits Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rits Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
